恒瑞医药(600276.SH)：药品上市许可申请获受理

Core Viewpoint - Heng Rui Medicine (600276.SH) has received a drug registration application acceptance notice from the National Medical Products Administration for its innovative drug, injection of Carrelizumab combined with Apalutamide capsules, intended for first-line treatment of recurrent or metastatic cervical cancer patients [1] Group 1 - The company and its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., are involved in the development of innovative drugs [1] - The acceptance of the drug registration application marks a significant step towards potential market entry for the treatment of cervical cancer [1]